Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chappell

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
MMWR. Morbidity and Mortality Weekly Report|August 26, 2021
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021Mark W Tenforde, Wesley H Self, Eric A Naioti, et al.
MMWR. Morbidity and Mortality Weekly Report|January 27, 2022
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021Mark W Tenforde, Manish M Patel, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United StatesKatherine Adams, Jillian P Rhoads, Diya Surie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2022
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United StatesNathaniel M Lewis, Wesley H Self, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
The Journal of Infectious Diseases|December 21, 2021
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021Nathaniel M Lewis, Eric A Naioti, Wesley H Self, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022Mark W Tenforde, Wesley H Self, Manjusha Gaglani, et al.
Nature|August 7, 2020
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessKizzmekia S Corbett, Darin K Edwards, Sarah R Leist, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
MMWR. Morbidity and Mortality Weekly Report|August 26, 2021
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021Mark W Tenforde, Wesley H Self, Eric A Naioti, et al.
MMWR. Morbidity and Mortality Weekly Report|January 27, 2022
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021Mark W Tenforde, Manish M Patel, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United StatesKatherine Adams, Jillian P Rhoads, Diya Surie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2022
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United StatesNathaniel M Lewis, Wesley H Self, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
The Journal of Infectious Diseases|December 21, 2021
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021Nathaniel M Lewis, Eric A Naioti, Wesley H Self, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022Mark W Tenforde, Wesley H Self, Manjusha Gaglani, et al.
Nature|August 7, 2020
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessKizzmekia S Corbett, Darin K Edwards, Sarah R Leist, et al.
Pageof 25